WO2023118263 - AGONISTS FOR TREATMENT OF EATING DISORDER
National phase entry is expected:
Publication Number
WO/2023/118263
Publication Date
29.06.2023
International Application No.
PCT/EP2022/087180
International Filing Date
21.12.2022
Title **
[English]
AGONISTS FOR TREATMENT OF EATING DISORDER
[French]
AGONISTES POUR LE TRAITEMENT D'UN TROUBLE DE L'ALIMENTATION
Applicants **
NOVO NORDISK A/S
Novo Alle 1
2880 Bagsværd, DK
Inventors
EKBERG, Jeppe Hvidtfeldt
Ludvig Holsteins Alle 19
2750 Ballerup, DK
CHRISTENSEN, Dan Ploug
Gammel Kalkbrænderi Vej 14, 1.th.
2100 København Ø, DK
HANSEN, Jakob Bondo
Brorsonsgade 6, 3
1624 Copenhagen V, DK
Priority Data
21216389.3
21.12.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1793 | |
| EPO | Filing, Examination | 12464 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 6110 |
Total: 21531 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to neurokinin receptor (NKR) agonists for use in treatment of an eating disorder, such as binge eating disorder.[French]
La présente invention concerne des agonistes du récepteur de la neurokinine (NKR) destinés à être utilisés dans le traitement d'un trouble de l'alimentation, tel que l'hyperphagie boulimique.